JO
AMLX icon

John Overdeck’s Amylyx Pharmaceuticals AMLX Stock Holding History

John Overdeck’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7M Buy
593,435
+431,490
+266% +$6.67M 0.01% 1478
2026
Q1 		$2.25M Sell
161,945
-182,456
-53% -$2.57M ﹤0.01% 2668
2025
Q4 		$4.16M Buy
344,401
+245,985
+250% +$3.34M 0.01% 1876
2025
Q3 		$1.34M Sell
98,416
-460,430
-82% -$4.33M ﹤0.01% 2395
2025
Q2 		$3.58M Sell
558,846
-203,207
-27% -$988K 0.01% 1447
2025
Q1 		$2.7M Buy
762,053
+110,536
+17% +$393K 0.01% 1546
2024
Q4 		$2.46M Buy
651,517
+284,280
+77% +$1.34M 0.01% 1579
2024
Q3 		$1.19M Sell
367,237
-930,601
-72% -$2.09M ﹤0.01% 2024
2024
Q2 		$2.47M Sell
1,297,838
-135,027
-9% -$262K 0.01% 1414
2024
Q1 		$4.07M Buy
1,432,865
+1,389,065
+3,171% +$18.2M 0.01% 1085
2023
Q4 		$645K Buy
+43,800
New +$671K ﹤0.01% 2326

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

John Overdeck's AMLX Position: Q2 2026 in Review

John Overdeck increased its Amylyx Pharmaceuticals (AMLX) stake by 266% in Q2 2026, buying an estimated $6.67M and bringing the position to 593,435 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #1478.

John Overdeck first reported a position in AMLX in Q4 2023 and has held it in 11 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • John Overdeck held 593,435 shares of Amylyx Pharmaceuticals worth $10.7M as of Q2 2026.
  • John Overdeck bought 431,490 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $6.67M.
  • Amylyx Pharmaceuticals made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1478 holding.
  • John Overdeck first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.